Compare Honeywell International Inc (HON) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs TG Therapeutics Inc — how do they compare? Honeywell International Inc trades at $229.22 (market cap $71.66B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Honeywell International Inc is far larger — about 8.7× TG Therapeutics Inc's market cap, and Honeywell International Inc pays a 4.21% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HON | TGTX | |
|---|---|---|
Market Cap | $71.66B | $8.26B |
Sector | Industrials | Health |
52-Week High | $248.04 | $59.06 |
52-Week Low | $188.14 | $26.39 |
Enterprise Value | $96.01B | $8.50B |
Dividend Yield | 4.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $229.86, up 2.15% with a bullish technical signal and strong analyst support. The company maintains solid profitability with 10.89% net margin and 26.41% ROE, though recent earnings show some pressure with Q2 2026 expectations at $1.80 EPS. Recent developments include a completed 2:1 reverse stock split and the acquisition of Johnson Matthey's Catalyst Technologies business for £1.325 billion, positioning the company for growth in automation and industrial technology.
HON presents a compelling investment case with 65% analyst buy ratings and a $368.55 consensus price target representing 60% upside. However, risks include declining profit margins (12.63% in 2025 vs 14.81% in 2024), increasing debt-to-asset ratio (46.65% in 2025), and near-term earnings uncertainty post-spinoffs. The stock's valuation at 18.07 P/E appears reasonable given its market leadership and strategic repositioning.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
